JG
ANAB icon

Joel Greenblatt’s AnaptysBio ANAB Stock Holding History

Joel Greenblatt’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$425K Sell
6,292
-7,680
-55% -$466K ﹤0.01% 1554
2026
Q1 		$775K Buy
+13,972
New +$752K ﹤0.01% 1377

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Joel Greenblatt's ANAB Position: Q2 2026 in Review

Joel Greenblatt reduced its AnaptysBio (ANAB) stake by 55% in Q2 2026, selling an estimated $466K and leaving 6,292 shares worth $425K. The position accounts for ﹤0.01% of the portfolio, ranked #1554.

Joel Greenblatt first reported a position in ANAB in Q1 2026 and has held it in 2 quarters since. The position peaked at $775K in Q1 2026. 211 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • Joel Greenblatt held 6,292 shares of AnaptysBio worth $425K as of Q2 2026.
  • Joel Greenblatt sold 7,680 AnaptysBio shares in Q2 2026, an estimated $466K.
  • AnaptysBio made up ﹤0.01% of Joel Greenblatt's portfolio in Q2 2026, its #1554 holding.
  • Joel Greenblatt first reported a position in AnaptysBio in Q1 2026 and has held it in 2 quarters since.
  • Joel Greenblatt's AnaptysBio position peaked at $775K in Q1 2026.
  • 211 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.